Teclistamab–Daratumumab Approved for Relapsed/Refractory Myeloma
Episode Summary
Long-term levothyroxine therapy in older adults may modestly reduce cardiovascular risk when carefully monitored, but clinicians must balance benefits with risks like atrial fibrillation and bone loss.